Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammatory diseases
Biotech
Merck’s anti-TL1A secures a ph. 2 hidradenitis suppurativa win
The study met its primary and secondary endpoints at week 16, informing phase 3 development for tulisokibart in HS.
Marissa Russo
Sep 30, 2026 10:20am
Electra charges up with $350M from upsized IPO
Sep 18, 2026 2:58am
Electra seeks $342M IPO to power inflammatory drug’s ph. 3 push
Sep 14, 2026 8:52am
Metsera duo power Sentivera to $1.5B inflammatory disease deal
Aug 25, 2026 9:24am
Merck posts 1 win, 1 loss in phase 2 inflammatory disease trials
Aug 4, 2026 6:30am
cAMPfield harvests $180M series A to advance oral IBD asset
Jun 18, 2026 10:34am
